Product

Hepatosil Advanced

Silymarin + L-Ornithine-L-Aspartate + S-Adenosylmethionine + Artichoke Dry Extract + Vitamin E · VetaPro / Veterinarstvo

1 form: tablet. Not applicable (not a medicine).

Forms and dosesNot applicable (not a medicine)

Form	Dose	Frequency	Georgia
30 tablets, Tablet	No label dose in the reference yet	-	Georgia Not a medicine Not applicable (not a medicine) VetaPro exact product category Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration Hepatosil Advanced 30 tablets, Tablet complementary feed for dogs and cats vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder 4.6/10 Weak evidence support vetman assessment Hepatosil Advanced 30 tablets, complementary feed for dogs and cats Assessed clinical scopeDog · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring vetman score 4.6/10 Weak evidence support Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026 A transparent-category but weakly outcome-supported complementary feed. It may be used as a monitored adjunct, but exact-product evidence, quantitative label transparency and dose/formulation certainty do not support stronger claims. Regulatory and scientific credibility4.5/10 Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists. Clinical efficacy3.0/10 Ingredient mechanisms and limited dog studies are plausible, but consensus and reviews find weak clinical-outcome evidence; no Hepatosil trial exists, and recent SAMe+silymarin data showed minimal effect without disease-specific therapy. Safety and tolerability5.5/10 The ingredients are commonly used adjuncts and serious toxicity is not prominent in indirect sources, but exact-product adverse-event rates, long-term diseased-dog safety, interaction testing and reproductive data are absent. Clinical practicality6.0/10 Once-daily oral use is manageable, but fasting/food separation, double-coat versus crushing uncertainty, ambiguous dosing above 10 kg and undefined duration add meaningful burden. Full-course cost-effectiveness- Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded. Important safety and use flags This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety. Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention. No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof. The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information. At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen. The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response. The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters. Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free. Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses. Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review. Assessment sources Hepatosil VetaPro page2026 Hepatosil leaflet copy2026 Hepatosil category audit2026 ACVIM canine hepatitis consensus2019 Canine liver nutraceutical review2013 Canine prednisolone SAMe trial2005 Canine GBM hepatoprotectant trial2025 Canine IV LOLA report2016 Healthy-cat SAMe study2005 Feline acetaminophen SAMe study2003 Veterinary cytoprotectant review2009 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder 4.1/10 Weak evidence support vetman assessment Hepatosil Advanced 30 tablets, complementary feed for dogs and cats Assessed clinical scopeCat · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring vetman score 4.1/10 Weak evidence support Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026 A weakly supported complementary feed with especially indirect feline evidence and an unvalidated half-tablet dose unit. It should not replace diagnosis, disease-specific treatment or a validated cat-sized product. Regulatory and scientific credibility4.5/10 Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists. Clinical efficacy2.5/10 Feline evidence consists mainly of small experimental SAMe studies using different enteric-coated products; it does not establish benefit for spontaneous feline liver disease or this five-ingredient tablet. Safety and tolerability5.0/10 A small healthy-cat study supports tolerability of a different SAMe product, but exact-formulation safety in ill cats, interactions, long-term use and reproductive groups are unestablished. Clinical practicality4.5/10 Once-daily use is simple, but the unscored half-tablet dose is not accuracy-validated, fasting and coating/crushing uncertainty remain, and a separate MINI presentation is better matched to small animals. Full-course cost-effectiveness- Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded. Important safety and use flags This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety. Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention. No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof. The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information. At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen. The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response. The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters. Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free. Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses. Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review. Assessment sources Hepatosil VetaPro page2026 Hepatosil leaflet copy2026 Hepatosil category audit2026 ACVIM canine hepatitis consensus2019 Canine liver nutraceutical review2013 Canine prednisolone SAMe trial2005 Canine GBM hepatoprotectant trial2025 Canine IV LOLA report2016 Healthy-cat SAMe study2005 Feline acetaminophen SAMe study2003 Veterinary cytoprotectant review2009 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Silymarin250 mg L-Ornithine-L-Aspartate50 mg S-Adenosylmethionine45 mg Artichoke Dry Extract40 mg Vitamin E20 mg Formulation Type Tablet Administration route By mouth Manufacturer VetaPro / Veterinarstvo · Serbia Registration Georgia Not a medicine Not applicable (not a medicine) VetaPro exact product category Verified on: 22 Oct 2026 EU Not a medicine Not applicable (not a medicine) VetaPro exact product category Verified on: 22 Oct 2026 UK Not a medicine Not applicable (not a medicine) VetaPro exact product category Verified on: 22 Oct 2026 US Not a medicine Not applicable (not a medicine) VetaPro exact product category Verified on: 22 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026 Information not fully verified Adjunctive nutritional/hepatoprotective support only after diagnosis and disease-specific management. The manufacturer states one tablet up to 10 kg daily; a retailer-reproduced leaflet states dog one tablet/10 kg and cat half tablet/5 kg daily on an empty stomach. Do not extend the ambiguous schedule above 10 kg or assume an unscored half is equal-dose. A separate MINI presentation exists for small animals.

The dose of a combination product is determined by its own product information. The doses below apply to the individual active substances and should not be used as the dose of this product.

Active substance doses, with sources

Active substance L-Ornithine-L-Aspartate

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Dose	Species	Indication	Route	Frequency	Source
616 mg/kg off-label	Dog	Hepatic Encephalopathy	Intravenous	daily for 1 day	Ahn et al. 2016 Scientific article A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs Journal of Veterinary Science, 2016 Open the source ↗
1232 mg/kg off-label	Dog	Hepatic Encephalopathy Emergency	Intravenous	per day	Ahn et al. 2016 Scientific article A study or review published in a scientific journal. Its findings apply to the animals and conditions it studied. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs Journal of Veterinary Science, 2016 Open the source ↗

Active substance S-Adenosylmethionine

Dose	Species	Indication	Route	Frequency	Source
18 mg/kg off-label	Dog, Cat	Maintenance	By mouth	once daily	MSD Vet Manual 2024 Reference book A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose. Drugs That Affect Digestive Functions in Monogastric Animals MSD/Merck Veterinary Manual, 2024 Open the source ↗

Silymarin: No dose supported by a publicly verifiable source yet

Artichoke Dry Extract: No dose supported by a publicly verifiable source yet

Vitamin E: No dose supported by a publicly verifiable source yet

Known Contraindications

Critical L-Ornithine-L-Aspartate
if you suffer from severely impaired kidney function (renal insufficiency). A serum creatinine value over 3 mg/100 ml can be used as a guideline value.

Sources: Product label
Critical L-Ornithine-L-Aspartate
Known hypersensitivity to L-ornithine L-aspartate is a contraindication.

Sources: Product label
Warning L-Ornithine-L-Aspartate (Cat)
No dose has been established for cats. The only identified veterinary publication concerns dogs, and even that dose was extrapolated from human medicine. Use in cats therefore requires an individual veterinary decision.
Caution L-Ornithine-L-Aspartate
Do not administer ornithine aspartate infusion concentrate intra-arterially.

Sources: Product label

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Hepatosil Advanced

Forms and dosesNot applicable (not a medicine)

Hepatosil Advanced 30 tablets, Tablet

Known Contraindications

Related products

Same therapeutic group 65

All of this shows in vetman as you prescribe